Current Report Filing (8-k)
July 02 2018 - 8:53AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
July 2, 2018
ENOCHIAN BIOSCIENCES INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-54478
|
|
45-2559340
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
Century City Medical Plaza
2080 Century City East
Suite 906
Los Angeles, CA 90067
(Address of principal executive offices)
|
+1(510) 203-4857
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01 Other Events.
On July
2, 2018, Enochian Biosciences, Inc. distributed a Letter to its Shareholders from its Chief Executive Officer and Chairman of
the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information
included in this Item 8.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
The Company undertakes
no duty or obligation to update or revise information included in this Report or the Exhibit.
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ENOCHIAN BIOSCIENCES, INC.
|
|
|
|
By:
|
/s/ Eric J. Leire
|
|
|
Name: Eric J. Leire
Title: Chief Executive Officer
|
Date: July 2, 2018
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Sep 2023 to Sep 2024